Brazil's health regulatory agency, Anvisa, has banned the sale and distribution of counterfeit Mounjaro units across the country [1].
The seizure of these illicit medications is critical because unregulated drugs can contain incorrect dosages or harmful contaminants, posing immediate risks to patients using them for chronic health conditions.
Anvisa officials determined that three falsified batches of the medication, tirzepatide, were circulating in the national market [1]. The seized units were specifically in dosages of 10 mg and 15 mg [1]. These products did not possess the required registration with the agency, making them illegal for sale or use in Brazil [1].
"A Anvisa determinou a apreensão imediata e proibiu a comercialização, distribuição e o uso de unidades falsificadas do medicamento Mounjaro em território nacional," a spokesperson for Anvisa said [1].
The agency issued the order on June 2, 2024 [1]. This action follows reports of counterfeit pharmaceuticals entering the supply chain, a growing concern for high-demand medications.
"Essas unidades não possuem registro na Anvisa e podem representar risco à saúde dos pacientes," the spokesperson said [1].
Authorities have ordered the immediate seizure of any remaining units from these specific batches to prevent further patient exposure. The agency continues to monitor the distribution channels to identify the source of the falsified tirzepatide [1].
“These units do not have registration with Anvisa and may represent a risk to the health of patients.”
The seizure of counterfeit tirzepatide highlights the vulnerability of the global pharmaceutical supply chain to illicit actors, particularly as demand for weight-loss and diabetes medications surges. By targeting specific dosages and requiring strict registration, Anvisa is attempting to curb a black market that bypasses safety protocols, emphasizing that the lack of regulatory oversight in counterfeit drugs can lead to unpredictable and dangerous clinical outcomes for patients.
